Ionis Pharma rises after US FDA approves genetic disorder drug

** Shares of drugmaker Ionis Pharmaceuticals IONS.O rise 3.2% to $44.20

** Company says the U.S. FDA has approved its drug to prevent instances of severe swelling in various parts of the body of patients with a rare genetic disorder

** It says the drug, Dawnzera, will be available in the U.S. in the coming days

** The drug is approved to prevent symptoms of a rare genetic disease called hereditary angioedema (HAE) in adults and pediatric patients over 12 years old

** HAE causes frequent attacks of severe swelling in various parts of the body, including the hands, feet, genitals and face

** Including session moves, stock up 22.2% YTD